日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4

前列腺癌患者的试验设计和目标:前列腺癌工作组4的建议

Armstrong, Andrew J; Morris, Michael J; Abida, Wassim; Aggarwal, Rahul R; Antonarakis, Emmanuel S; Attard, Gerhardt; Beltran, Himisha; Bryce, Alan; Carducci, Michael A; Cheng, Heather H; Chen, Delphine L; Chi, Kim N; Childs, Daniel S; Dahut, William; Emmett, Louise; Fizazi, Karim; Gafita, Andrei; George, Daniel J; Hermann, Ken; Hofman, Michael S; Hope, Thomas; Hussain, Maha; Kelly, W Kevin; Kessler, Elizabeth; Kuo, Phillip H; Lang, Joshua; Liu, Glenn; Marshall, Catherine H; Morgans, Alicia K; McKay, Rana R; Nanus, David; Nelson, Peter; Paller, Channing; Reichert, Zachery R; Ryan, Charles J; Sartor, A Oliver; Schöder, Heiko; Schwartz, Lawrence H; Sharifi, Nima; Stadler, Walter M; Stein, Mark; Sternberg, Cora N; Szmulewitz, Russell Z; Tagawa, Scott T; Sokolova, Alexandra O; Wyatt, Alex W; Yamoah, Kosj; Yu, Evan Y; Halabi, Susan; Scher, Howard I

Two Decades of Disease Evolution and Biomarker-Guided Clinical Decision Making in Metastatic Prostate Cancer

转移性前列腺癌疾病演变二十年及生物标志物指导的临床决策

Erazo, Tatiana; Moiso, Enrico; Aras, Omer; Scher, Howard I

Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer

奥拉帕尼和度伐利尤单抗治疗伴有DNA损伤修复改变和生化复发性前列腺癌的患者

Autio, Karen A; McHugh, Deaglan J; Rathkopf, Dana E; Xiao, Han; Merugu, Swathi; Wong, Phillip; Jan, Mehrin; Dorff, Tanya B; Heath, Elisabeth I; Scher, Howard I

A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes

一项针对转移性去势抵抗性前列腺癌且无DNA损伤反应基因突变患者的1b/2期研究,评估间歇性使用他拉唑帕尼联合替莫唑胺的疗效。

Autio, Karen A; Kyriakopoulos, Christos E; Palyca, Paul; Xiao, Han; Emamekhoo, Hamid; Danila, Daniel; Jan, Mehrin; Catharine, Victoria; Riedel, Elyn; Devitt, Michael; Laird, A Douglas; Scher, Howard I

Retraction: MiR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/β-catenin pathway

撤稿:miR-744通过激活Wnt/β-catenin通路增强胰腺癌的致瘤性

Roskes, Marjorie L; Martinez-Fundichely, Alexander; Cohen, Sandra; Balaban, Metin; Wong, Chen Khuan; Li, Weiling; Gonzalez, Tonatiuh A; Tehim, Anisha B; Xu, Hao; ElNaggar, Shahd; Myers, Matthew; Bareja, Rohan; Dorsaint, Princesca; Gorski, Kathryn; Asad, Muhammad; Assaad, Majd Al; Robinson, Brian D; Sigouros, Michael; Barnett, Ethan; Manohar, Jyothi; Tagawa, Scott; Nanus, David; Molina, Ana; Nauseef, Jones T; Sternberg, Cora N; Mosquera, Juan Miguel; Scher, Howard I; Sboner, Andrea; Raphael, Benjamin J; Chen, Yu; Khurana, Ekta; Zhou, Wei; Li, Yongfeng; Gou, Shanmiao; Xiong, Jiongxin; Wu, Heshui; Wang, Chunyou; Yan, Haijiao; Liu, Tao

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer

前列腺癌患者的微卫星不稳定性、肿瘤突变负荷和免疫检查点阻断疗法反应

Lenis, Andrew T; Ravichandran, Vignesh; Brown, Samantha; Alam, Syed M; Katims, Andrew; Truong, Hong; Reisz, Peter A; Vasselman, Samantha; Nweji, Barbara; Autio, Karen A; Morris, Michael J; Slovin, Susan F; Rathkopf, Dana; Danila, Daniel; Woo, Sungmin; Vargas, Hebert A; Laudone, Vincent P; Ehdaie, Behfar; Reuter, Victor; Arcila, Maria; Berger, Michael F; Viale, Agnes; Scher, Howard I; Schultz, Nikolaus; Gopalan, Anuradha; Donoghue, Mark T A; Ostrovnaya, Irina; Stopsack, Konrad H; Solit, David B; Abida, Wassim

Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer

雄激素剥夺疗法驱动局限性前列腺癌产生独特的免疫表型

Dallos, Matthew C; Obradovic, Aleksandar Z; McCann, Patrick; Chowdhury, Nivedita; Pratapa, Aditya; Aggen, David H; Gaffney, Christopher; Autio, Karen A; Virk, Renu K; De Marzo, Angelo M; Antonarakis, Emmanuel S; Scher, Howard I; Drake, Charles G; Rathkopf, Dana E

Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies

单细胞分析治疗耐药性前列腺癌:细胞状态变化对细胞表面抗原靶向治疗的意义

Zaidi, Samir; Park, Jooyoung; Chan, Joseph M; Roudier, Martine P; Zhao, Jimmy L; Gopalan, Anuradha; Wadosky, Kristine M; Patel, Radhika A; Sayar, Erolcan; Karthaus, Wouter R; Kates, D Henry; Chaudhary, Ojasvi; Xu, Tianhao; Masilionis, Ignas; Mazutis, Linas; Chaligné, Ronan; Obradovic, Aleksandar; Linkov, Irina; Barlas, Afsar; Jungbluth, Achim A; Rekhtman, Natasha; Silber, Joachim; Manova-Todorova, Katia; Watson, Philip A; True, Lawrence D; Morrissey, Colm; Scher, Howard I; Rathkopf, Dana E; Morris, Michael J; Goodrich, David W; Choi, Jungmin; Nelson, Peter S; Haffner, Michael C; Sawyers, Charles L

Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy

在PARP抑制剂和铂类化疗的治疗压力下,BRCA2回复突变趋同进化

Walmsley, Charlotte S; Jonsson, Philip; Cheng, Michael L; McBride, Sean; Kaeser, Christopher; Vargas, Herbert Alberto; Laudone, Vincent; Taylor, Barry S; Kappagantula, Rajya; Baez, Priscilla; Richards, Allison L; Noronha, Anne Marie; Perera, Dilmi; Berger, Michael; Solit, David B; Iacobuzio-Donahue, Christine A; Scher, Howard I; Donoghue, Mark T A; Abida, Wassim; Schram, Alison M

Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer

转移性HER2突变肺癌患者的最佳系统治疗及ctDNA的实际临床应用

Liu, Si-Yang; Erazo, Tatiana; Jee, Justin; Arfe, Andrea; Gupta, Avantika; Pike, Luke R G; Santini, Fernando C; Daly, Bobby; Schoenfeld, Adam; Eichholz, Jordan; Johnson, Kaylie; Martinez, Andres; Sui, Jane; Riaz, Nadeem; Chang, Jason; Yang, Soo-Ryum; Travis, William; Arcila, Maria E; Guo, Jiannan; Gagne, Eric; Garg, Kavita; Baehner, Frederick; Lee, Nancy Y; Drilon, Alexander; Kris, Mark G; Scher, Howard I; Razavi, Pedram; Gomez, Daniel R; Jones, David R; Rudin, Charles M; Chandarlapaty, Sarat; Isbell, James M; Li, Bob T